Amphenol Corp. Cl A Stock Rallies 4.1%, Outperforms Peers
Dow Jones2026/09/21 20:35This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Amphenol Corp. Cl A rallied 4.1% to $80.72 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 1.5% to 7,764.70 and the Dow Jones Industrial Average rising 0.7% to 52,048.83.
Amphenol Corp. Cl A closed 9.6% below its 52-week high of $89.26, which the company achieved on June 30th.
The stock outperformed some of its peers, as Eaton Corp. PLC rose 2.5% to $435.43, TE Connectivity PLC rose 2.2% to $210.01, and Enphase Energy Inc. rose 0.35% to $34.76.
Trading volume totaled 11.6 million, compared to the 50-day average of 12.6 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 21, 2026 16:35 ET (20:35 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BNP Paribas gives Microsoft (MSFT.US) a "Buy" rating: Azure price increases will be gradually implemented after contract renewals, and a deal with SpaceX may be announced soon.
BNP Paribas has rated Microsoft as "Buy" with a target price of $549.
Iranian President will head to New York for UN meeting
"Big Short" Burry opens a position in QXO (QXO.US), betting on building products integration and undervaluation; stock price rises over 7%
Investor Michael Burry disclosed that he has purchased common and preferred shares of QXO (QXO.US), a building products company, citing its integration strategy and the currently depressed stock price. The stock surged 7.2% on Monday.
700,000 new elderly patients join, Eli Lilly (LLY.US) dominates 70%: The first Medicare weight loss drug coverage report released
Dave Ricks, CEO of Eli Lilly (LLY.US), said in an interview on Monday that since Medicare began coverage for obesity drugs in July, 700,000 new elderly patients have started using GLP-1 medications.